81 research outputs found
Neglected obstetric haemorrhage leading to acute kidney injury
Pregnancy related acute kidney injury takes substantial share of acute kidney injury (AKI) in India, with obstetrical haemorrhage having high morbidity and mortality. A young female had neglected obstetric haemorrhage (unrecognized intrauterine and massive intraperitoneal bleeding post caesarean, due to uterine trauma and atony) and dangerous intra-abdominal hypertension with exsanguination eventually leading to shock, multifactorial AKI, metabolic acidosis, and hyperkalemia. Intensive and aggressive management with subtotal hysterectomy, inotropes, fluid management, mechanical ventilation, tracheostomy, and hemodialysis changed the outcome. Despite odds against, neglected obstetric haemorrhage with complicated AKI, was managed successfully by emergency hysterectomy, aggressive intervention for AKI with intensive fluid, ventilatory management and daily hemodialysis. Timely identification and aggressive management of this condition and complications is pivotal in preventing complications, morbidity, and maternal mortality.
Adrenal hormones mediate disease tolerance in malaria
Malaria reduces host fitness and survival by pathogen-mediated damage and inflammation. Disease tolerance mechanisms counter these negative effects without decreasing pathogen load. Here, we demonstrate that in four different mouse models of malaria, adrenal hormones confer disease tolerance and protect against early death, independently of parasitemia. Surprisingly, adrenalectomy differentially affects malaria-induced inflammation by increasing circulating cytokines and inflammation in the brain but not in the liver or lung. Furthermore, without affecting the transcription of hepatic gluconeogenic enzymes, adrenalectomy causes exhaustion of hepatic glycogen and insulin-independent lethal hypoglycemia upon infection. This hypoglycemia is not prevented by glucose administration or TNF-alpha neutralization. In contrast, treatment with a synthetic glucocorticoid (dexamethasone) prevents the hypoglycemia, lowers cerebral cytokine expression and increases survival rates. Overall, we conclude that in malaria, adrenal hormones do not protect against lung and liver inflammation. Instead, they prevent excessive systemic and brain inflammation and severe hypoglycemia, thereby contributing to tolerance
Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990-2019 : a systematic analysis from the Global Burden of Disease Study 2019
Interpretation Chewing tobacco remains a substantial public health problem in several regions of the world, and predominantly in south Asia. We found little change in the prevalence of chewing tobacco use between 1990 and 2019, and that control efforts have had much larger effects on the prevalence of smoking tobacco use than on chewing tobacco use in some countries. Mitigating the health effects of chewing tobacco requires stronger regulations and policies that specifically target use of chewing tobacco, especially in countries with high prevalence. Findings In 2019, 273 center dot 9 million (95% uncertainty interval 258 center dot 5 to 290 center dot 9) people aged 15 years and older used chewing tobacco, and the global age-standardised prevalence of chewing tobacco use was 4 center dot 72% (4 center dot 46 to 5 center dot 01). 228 center dot 2 million (213 center dot 6 to 244 center dot 7; 83 center dot 29% [82 center dot 15 to 84 center dot 42]) chewing tobacco users lived in the south Asia region. Prevalence among young people aged 15-19 years was over 10% in seven locations in 2019. Although global agestandardised prevalence of smoking tobacco use decreased significantly between 1990 and 2019 (annualised rate of change: -1 center dot 21% [-1 center dot 26 to -1 center dot 16]), similar progress was not observed for chewing tobacco (0 center dot 46% [0 center dot 13 to 0 center dot 79]). Among the 12 highest prevalence countries (Bangladesh, Bhutan, Cambodia, India, Madagascar, Marshall Islands, Myanmar, Nepal, Pakistan, Palau, Sri Lanka, and Yemen), only Yemen had a significant decrease in the prevalence of chewing tobacco use, which was among males between 1990 and 2019 (-0 center dot 94% [-1 center dot 72 to -0 center dot 14]), compared with nine of 12 countries that had significant decreases in the prevalence of smoking tobacco. Among females, none of these 12 countries had significant decreases in prevalence of chewing tobacco use, whereas seven of 12 countries had a significant decrease in the prevalence of tobacco smoking use for the period. Summary Background Chewing tobacco and other types of smokeless tobacco use have had less attention from the global health community than smoked tobacco use. However, the practice is popular in many parts of the world and has been linked to several adverse health outcomes. Understanding trends in prevalence with age, over time, and by location and sex is important for policy setting and in relation to monitoring and assessing commitment to the WHO Framework Convention on Tobacco Control. Methods We estimated prevalence of chewing tobacco use as part of the Global Burden of Diseases, Injuries, and Risk Factors Study 2019 using a modelling strategy that used information on multiple types of smokeless tobacco products. We generated a time series of prevalence of chewing tobacco use among individuals aged 15 years and older from 1990 to 2019 in 204 countries and territories, including age-sex specific estimates. We also compared these trends to those of smoked tobacco over the same time period. Findings In 2019, 273 & middot;9 million (95% uncertainty interval 258 & middot;5 to 290 & middot;9) people aged 15 years and older used chewing tobacco, and the global age-standardised prevalence of chewing tobacco use was 4 & middot;72% (4 & middot;46 to 5 & middot;01). 228 & middot;2 million (213 & middot;6 to 244 & middot;7; 83 & middot;29% [82 & middot;15 to 84 & middot;42]) chewing tobacco users lived in the south Asia region. Prevalence among young people aged 15-19 years was over 10% in seven locations in 2019. Although global age standardised prevalence of smoking tobacco use decreased significantly between 1990 and 2019 (annualised rate of change: -1 & middot;21% [-1 & middot;26 to -1 & middot;16]), similar progress was not observed for chewing tobacco (0 & middot;46% [0 & middot;13 to 0 & middot;79]). Among the 12 highest prevalence countries (Bangladesh, Bhutan, Cambodia, India, Madagascar, Marshall Islands, Myanmar, Nepal, Pakistan, Palau, Sri Lanka, and Yemen), only Yemen had a significant decrease in the prevalence of chewing tobacco use, which was among males between 1990 and 2019 (-0 & middot;94% [-1 & middot;72 to -0 & middot;14]), compared with nine of 12 countries that had significant decreases in the prevalence of smoking tobacco. Among females, none of these 12 countries had significant decreases in prevalence of chewing tobacco use, whereas seven of 12 countries had a significant decrease in the prevalence of tobacco smoking use for the period. Interpretation Chewing tobacco remains a substantial public health problem in several regions of the world, and predominantly in south Asia. We found little change in the prevalence of chewing tobacco use between 1990 and 2019, and that control efforts have had much larger effects on the prevalence of smoking tobacco use than on chewing tobacco use in some countries. Mitigating the health effects of chewing tobacco requires stronger regulations and policies that specifically target use of chewing tobacco, especially in countries with high prevalence. Copyright (c) 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.Peer reviewe
Recommended from our members
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
BACKGROUND Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING Bill & Melinda Gates Foundation
Deficiency of 11β-HSD1 modulates energy homeostasis in the brain following systemic inflammation
Chronically elevated brain glucocorticoid (GC) levels impair cognition. Age-related
cognitive deficits or "sickness" behaviour is often associated with neuroinflammation. In
rodents, raised GC levels prior to lipopolysaccharide (LPS) administration potentiate
neuroinflammation although GC suppresses neuroinflammation if administered after LPS.
11β-hydroxysteroid dehydrogenase-1 (11β-HSD1) reductase activity can increase
intracellular GC levels, including in the brain, without alteration in circulating levels.
Deficiency/pharmacological inhibition of 11β-HSD1 is protective against age related
cognitive impairment in both rodent and humans. However, the underlying mechanism
remains unclear.11β-HSD1 reductase activity is coupled to hexose-6-phosphate dehydrogenase activity, itself
dependent on cellular energy status. Processes affected by deficiency/inhibition of 11β-
HSD1 (e.g. acute inflammation, angiogenesis) are associated with increased glycolysis.
Additionally, compared to C57BL/6J controls, adipose tissue of 11β-HSD1 deficient mice
shows increased expression of glycolytic and oxidative metabolism genes in a rodent model
of obesity, characterised by low-grade chronic inflammation.I hypothesised that 11β-HSD1 has a role in regulation of cellular energetics basally and
following inflammation. 11β-HSD1 expression in the brain will be up-regulated during
systemic inflammation. Following inflammation, 11β-HSD1 deficiency will attenuate the
pro-inflammatory response and subsequently alter energy substrate uptake and/or utilisation
in the key areas of brain (i.e. hypothalamus and the hippocampus) that sense and respond to
inflammation and energy balance. To test my hypothesis, global 11β-HSD1 KO mice,
primary macrophages in vitro and murine models of inflammations were utilised.11β-HSD1 mRNA and protein expression were confirmed in the hypothalamus and the
hippocampus of C57BL/6J mice. In the absence of inflammation, expression of
inflammatory markers is low or negligible in the brains of Hsd11b1-/- mice similar to
C57BL/6J controls. However, compared to C57BL/6J, Hsd11b1-/- mice show altered mRNA
levels of metabolic transporters and enzymes in the hypothalamus and the hippocampus.
Overall, the mRNA profiling suggests reduced dependence on glucose in the brains of
Hsd11b1-/- mice, either through increased lactate availability (in the whole brain and
hippocampus) or through increased glycolysis and mitochondrial number/function (in the
hypothalamus).Primary macrophages were utilised to investigate the role of 11β-HSD1 in cellular energetics
in vitro. In these cell based assays, glycolysis was found to be the predominant glucose
metabolising pathway in C57BL/6J primary macrophages, consistent with the literature.
Preliminary data suggested reduced glycolytic activity in Hsd11b1-/- compared to C57BL/6J
primary macrophages. However, initial attempts to utilise these cell based assays on primary
microglia were unsuccessful. Moreover, Hsd11b1 mRNAs in the brain (down-regulation
with inflammation, discussed later) was found to be differentially regulated in comparison to
Hsd11b1 mRNA levels in the macrophages (up-regulation with inflammation) hence further
investigation was not pursued.To identify a model of peripheral inflammation where 11β-HSD1 is regulated in the brain in
vivo, Staph. aureus induced acute lung inflammation and the K/BxN serum transfer induced
model of arthritis were utilised. Increased expression of inflammatory markers in the brain
was associated with reduced Hsd11b1 mRNA levels in the hippocampus of control mice in
these models. Comparison of Hsd11b1-/- and C57BL/6J mice showed increased levels of
mRNAs encoding metabolic transporters in the hypothalamus and the hippocampus of
Hsd11b1-/- mice following inflammation in the K/BxN serum transfer model of arthritis
suggesting increased energy substrate availability. Additionally, increased levels of mRNA
encoding metabolic enzymes suggested increased glycolytic capacity and mitochondrial
oxidative phosphorylation activity in the hippocampus but not the hypothalamus of Hsd11b1-
/-, compared to C57BL/6J mice, following K/BxN serum induced arthritis. Overall, these
data suggest that the reduction in expression of 11β-HSD1 could be a potential mechanism to
increase energy substrate availability, glycolytic capacity and mitochondrial activity in the
hippocampus to provide metabolic support for neuronal metabolism and function following
peripheral inflammation.The role of 11β-HSD1 in the pro-inflammatory response and cellular energetics in the
hippocampus was further investigated in a well characterised sterile peritonitis model of
systemic inflammation in which a low to moderate dose of LPS was used. Mice were
administered LPS or vehicle (0.9% saline) by a single i.p. injection and culled 3h, 6h or 9h
post injection.Inflammation resulted in significant reduction in burrowing activity both in Hsd11b1-/- and
C57BL/6J mice suggesting sickness behaviour.. The number of circulating immune cells, as
a measure of peripheral inflammation, did not differ between genotypes. Similarly, plasma
corticosterone levels were elevated following inflammation but no genotype difference was
observed. However, levels of plasma 11-dehydrocorticosterone, the inert substrate for 11β-
HSD1, were significantly elevated in the Hsd11b1-/-, compared to C57BL/6J mice, following
inflammation. Levels of mRNA encoding inflammatory markers were lower in the
hippocampus of Hsd11b1-/-, compared to C57BL/6J mice, following inflammation. Also,
Hsd11b1 mRNA levels were reduced in the hippocampus of C57BL/6J mice following
inflammation, consistent with the finding above. Principal component analysis on levels of
mRNA encoding metabolite transporters and enzymes revealed a distinct metabolic response
in the hippocampus of Hsd11b1-/-, compared to C57BL/6J mice, 6h post LPS. At the same
time point in the hippocampus, levels of mRNAs encoding metabolite transporters and
enzymes suggested an attenuated switch to aerobic glycolysis with maintenance of
mitochondrial function/activity. Quantification of hippocampal energy metabolites using
targeted metabolomics in the Hsd11b1-/- compared to C57BL/6J mice 6h post LPS showed
correspondence with the mRNA results. Overall, these results suggest that reduced
expression of 11β-HSD1 could be a potential mechanism to reduce the pro-inflammatory
response and provide better metabolic support for neuronal function and metabolism in the
hippocampus, following systemic inflammation.In summary, the current work provides evidence for neuroprotection with 11β-HSD1
deficiency, following systemic inflammation. The suggestive neuroprotection is at least in
part mediated via an attenuated pro-inflammatory responses and increased energy substrate
uptake and/or utilisation providing better metabolic support for neuronal function following
inflammation. It argues for the development of tissue specific small molecule inhibitors of
11β-HSD1 that can cross the blood brain barrier as therapeutic agents against the adverse
cognitive effects of systemic inflammation and/or inflammaging
- …